Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 6 of 6 entries
Sorted by: Best Match Show Resources per page
The immune system in irritable bowel syndrome.

Journal of neurogastroenterology and motility

Barbara G, Cremon C, Carini G, Bellacosa L, Zecchi L, De Giorgio R, Corinaldesi R, Stanghellini V.
PMID: 22148103
J Neurogastroenterol Motil. 2011 Oct;17(4):349-59. doi: 10.5056/jnm.2011.17.4.349. Epub 2011 Oct 31.

The potential relevance of systemic and gastrointestinal immune activation in the pathophysiology and symptom generation in the irritable bowel syndrome (IBS) is supported by a number of observations. Infectious gastroenteritis is the strongest risk factor for the development of...

Cite
Barbara G, Cremon C, Carini G, et al. The immune system in irritable bowel syndrome. J Neurogastroenterol Motil. 2011;17(4):349-59doi: 10.5056/jnm.2011.17.4.349.
Barbara, G., Cremon, C., Carini, G., Bellacosa, L., Zecchi, L., De Giorgio, R., Corinaldesi, R., & Stanghellini, V. (2011). The immune system in irritable bowel syndrome. Journal of neurogastroenterology and motility, 17(4), 349-59. https://doi.org/10.5056/jnm.2011.17.4.349
Barbara, Giovanni, et al. "The immune system in irritable bowel syndrome." Journal of neurogastroenterology and motility vol. 17,4 (2011): 349-59. doi: https://doi.org/10.5056/jnm.2011.17.4.349
Barbara G, Cremon C, Carini G, Bellacosa L, Zecchi L, De Giorgio R, Corinaldesi R, Stanghellini V. The immune system in irritable bowel syndrome. J Neurogastroenterol Motil. 2011 Oct;17(4):349-59. doi: 10.5056/jnm.2011.17.4.349. Epub 2011 Oct 31. PMID: 22148103; PMCID: PMC3228974.
Copy Download .nbib Format: NLM
Implication of cytokines: Roles of tumor necrosis factor-alpha in liver injury.

Hepatology research : the official journal of the Japan Society of Hepatology

Nagaki M, Moriwaki H.
PMID: 19125946
Hepatol Res. 2008 Nov;38:S19-28. doi: 10.1111/j.1872-034X.2008.00422.x.

Acute liver failure caused by viruses, drugs, or liver resection, is marked by a massive degree of hepatocyte apoptosis and impaired hepatocyte proliferation, the mechanisms of which, however, still remain to be understood. The choice between life and death...

Cite
Nagaki M, Moriwaki H. Implication of cytokines: Roles of tumor necrosis factor-alpha in liver injury. Hepatol Res. 2008;38:S19-28doi: 10.1111/j.1872-034X.2008.00422.x.
Nagaki, M., & Moriwaki, H. (2008). Implication of cytokines: Roles of tumor necrosis factor-alpha in liver injury. Hepatology research : the official journal of the Japan Society of Hepatology, 38S19-28. https://doi.org/10.1111/j.1872-034X.2008.00422.x
Nagaki, Masahito, and Moriwaki, Hisataka. "Implication of cytokines: Roles of tumor necrosis factor-alpha in liver injury." Hepatology research : the official journal of the Japan Society of Hepatology vol. 38 (2008): S19-28. doi: https://doi.org/10.1111/j.1872-034X.2008.00422.x
Nagaki M, Moriwaki H. Implication of cytokines: Roles of tumor necrosis factor-alpha in liver injury. Hepatol Res. 2008 Nov;38:S19-28. doi: 10.1111/j.1872-034X.2008.00422.x. PMID: 19125946.
Copy Download .nbib Format: NLM
[Not Available].

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Sabbaj S, Kiyono H, McGhee JR.
PMID: 18031087
BioDrugs. 1997 Feb;7(2):134-57. doi: 10.2165/00063030-199707020-00006.

Oral delivery of vaccines results in these being taken up by specialised microfold epithelial cells covering Peyer's patches of the gastrointestinal tract, therefore stimulating regulatory T cells and surface IgA positive (sIgA+) B cells. T helper cells can be...

Cite
Sabbaj S, Kiyono H, McGhee JR. [Not Available]. BioDrugs. 1997;7(2):134-57doi: 10.2165/00063030-199707020-00006.
Sabbaj, S., Kiyono, H., & McGhee, J. R. (1997). [Not Available]. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 7(2), 134-57. https://doi.org/10.2165/00063030-199707020-00006
Sabbaj, S, et al. "[Not Available]." BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy vol. 7,2 (1997): 134-57. doi: https://doi.org/10.2165/00063030-199707020-00006
Sabbaj S, Kiyono H, McGhee JR. [Not Available]. BioDrugs. 1997 Feb;7(2):134-57. doi: 10.2165/00063030-199707020-00006. PMID: 18031087.
Copy Download .nbib Format: NLM
Detection of impaired IgG antibody formation facilitates the decision on early immunoglobulin replacement in hypogammaglobulinemic patients.

Frontiers in immunology

Wolf HM, Thon V, Litzman J, Eibl MM.
PMID: 25699049
Front Immunol. 2015 Feb 02;6:32. doi: 10.3389/fimmu.2015.00032. eCollection 2015.

Hypogammaglobulinemia (serum IgG lower than 2 SD below the age-matched mean) and clinical symptoms such as increased susceptibility to infection, autoimmune manifestations, granulomatous disease, and unexplained polyclonal lymphoproliferation are considered to be diagnostic hallmarks in patients with common variable...

Cite
Wolf HM, Thon V, Litzman J, et al. Detection of impaired IgG antibody formation facilitates the decision on early immunoglobulin replacement in hypogammaglobulinemic patients. Front Immunol. 2015;6:32doi: 10.3389/fimmu.2015.00032.
Wolf, H. M., Thon, V., Litzman, J., & Eibl, M. M. (2015). Detection of impaired IgG antibody formation facilitates the decision on early immunoglobulin replacement in hypogammaglobulinemic patients. Frontiers in immunology, 632. https://doi.org/10.3389/fimmu.2015.00032
Wolf, Hermann M, et al. "Detection of impaired IgG antibody formation facilitates the decision on early immunoglobulin replacement in hypogammaglobulinemic patients." Frontiers in immunology vol. 6 (2015): 32. doi: https://doi.org/10.3389/fimmu.2015.00032
Wolf HM, Thon V, Litzman J, Eibl MM. Detection of impaired IgG antibody formation facilitates the decision on early immunoglobulin replacement in hypogammaglobulinemic patients. Front Immunol. 2015 Feb 02;6:32. doi: 10.3389/fimmu.2015.00032. eCollection 2015. PMID: 25699049; PMCID: PMC4313720.
Copy Download .nbib Format: NLM
Epidemiologic Survey of Legionella Urine Antigen Testing Within a Large Wisconsin-Based Health Care System.

Journal of patient-centered research and reviews

Toberna CP, William HM, Kram JJF, Heslin K, Baumgardner DJ.
PMID: 32377550
J Patient Cent Res Rev. 2020 Apr 27;7(2):165-175. doi: 10.17294/2330-0698.1721. eCollection 2020.

PURPOSE: Legionella pneumophila pneumonia is a life-threatening, environmentally acquired infection identifiable via Legionella urine antigen tests (LUAT). We aimed to identify cumulative incidence, demographic distribution, and undetected disease outbreaks of Legionella pneumonia via positive LUAT in a single eastern...

Cite
Toberna CP, William HM, Kram JJF, et al. Epidemiologic Survey of Legionella Urine Antigen Testing Within a Large Wisconsin-Based Health Care System. J Patient Cent Res Rev. 2020;7(2):165-175doi: 10.17294/2330-0698.1721.
Toberna, C. P., William, H. M., Kram, J. J. F., Heslin, K., & Baumgardner, D. J. (2020). Epidemiologic Survey of Legionella Urine Antigen Testing Within a Large Wisconsin-Based Health Care System. Journal of patient-centered research and reviews, 7(2), 165-175. https://doi.org/10.17294/2330-0698.1721
Toberna, Caroline P, et al. "Epidemiologic Survey of Legionella Urine Antigen Testing Within a Large Wisconsin-Based Health Care System." Journal of patient-centered research and reviews vol. 7,2 (2020): 165-175. doi: https://doi.org/10.17294/2330-0698.1721
Toberna CP, William HM, Kram JJF, Heslin K, Baumgardner DJ. Epidemiologic Survey of Legionella Urine Antigen Testing Within a Large Wisconsin-Based Health Care System. J Patient Cent Res Rev. 2020 Apr 27;7(2):165-175. doi: 10.17294/2330-0698.1721. eCollection 2020. PMID: 32377550; PMCID: PMC7197889.
Copy Download .nbib Format: NLM
Camelid Single-Domain Antibodies for the Development of Potent Diagnosis Platforms.

Molecular diagnosis & therapy

Brilhante-da-Silva N, de Oliveira Sousa RM, Arruda A, Dos Santos EL, Marinho ACM, Stabeli RG, Fernandes CFC, Pereira SDS.
PMID: 34146333
Mol Diagn Ther. 2021 Jul;25(4):439-456. doi: 10.1007/s40291-021-00533-7. Epub 2021 Jun 19.

The distinct biophysical and pharmaceutical properties of camelid single-domain antibodies, referred to as VHHs or nanobodies, are associated with their nanometric dimensions, elevated stability, and antigen recognition capacity. These biomolecules can circumvent a number of diagnostic system limitations, especially...

Cite
Brilhante-da-Silva N, de Oliveira Sousa RM, Arruda A, et al. Camelid Single-Domain Antibodies for the Development of Potent Diagnosis Platforms. Mol Diagn Ther. 2021;25(4):439-456doi: 10.1007/s40291-021-00533-7.
Brilhante-da-Silva, N., de Oliveira Sousa, R. M., Arruda, A., Dos Santos, E. L., Marinho, A. C. M., Stabeli, R. G., Fernandes, C. F. C., & Pereira, S. D. S. (2021). Camelid Single-Domain Antibodies for the Development of Potent Diagnosis Platforms. Molecular diagnosis & therapy, 25(4), 439-456. https://doi.org/10.1007/s40291-021-00533-7
Brilhante-da-Silva, Nairo, et al. "Camelid Single-Domain Antibodies for the Development of Potent Diagnosis Platforms." Molecular diagnosis & therapy vol. 25,4 (2021): 439-456. doi: https://doi.org/10.1007/s40291-021-00533-7
Brilhante-da-Silva N, de Oliveira Sousa RM, Arruda A, Dos Santos EL, Marinho ACM, Stabeli RG, Fernandes CFC, Pereira SDS. Camelid Single-Domain Antibodies for the Development of Potent Diagnosis Platforms. Mol Diagn Ther. 2021 Jul;25(4):439-456. doi: 10.1007/s40291-021-00533-7. Epub 2021 Jun 19. PMID: 34146333.
Copy Download .nbib Format: NLM
Showing 1 to 6 of 6 entries